Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. November 2022 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022
31. Oktober 2022 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
06. Oktober 2022 16:05 ET
|
Mersana Therapeutics, Inc.
Topline data from UPLIFT expected in mid-2023Targeting potential Biologics License Application (BLA) submission by the end of 2023 CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. Oktober 2022 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies
30. September 2022 08:02 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, today announced the launch of Oncology FACETS: an...
Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer
12. September 2022 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Upcoming Investor Conferences
06. September 2022 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. September 2022 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers
16. August 2022 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
08. August 2022 16:04 ET
|
Mersana Therapeutics, Inc.
Approaching full enrollment in UPLIFT clinical trial; initiated patient screening in UP-NEXT clinical trialCleared INDs for XMT-1660 and XMT-2056Enhanced balance sheet with $100 million upfront option...